June 1 – 5, 2024
American Transplant Congress (ATC)
Philadelphia, PA
Meet us at Booth #720 to discover more about how you can help your transplant patients
June 5, 2024 - 6 pm EST
Advanced Strategies for CMV Management after SOT
Live Online Event
For the full scientific program, panel member list and registration click here
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/cytogam_logo.png)
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/cytogam-product.png)
CMV infection remains one of the most common complications for solid organ transplant recipients1 and is still considered “the troll of transplantation."2
As an immune globulin, CYTOGAM® offers a complementary mechanism of action to antiviral agents, working outside the cell, thus adding enhanced protection against CMV post-transplant.3,4,5
References
- Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(S1):S23-S31. doi: 10.1093/infdis/jiz454
- Stern A, Papnicolaou GA. CMV prevention and treatment in transplantation: what’s new in 2019. Curr Infect Dis Rep. 2019; 21(11): 45. doi:10.1007/s11908-019-0699-0
- Grossi PA, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016; 100: S1-S4
- Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100: S11-S18
- Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin versus ganciclovir alone. Transplantation. 2001;72(10):1647-1652
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/hepagam-b-logo.jpg)
HEPAGAM B is the only Hepatitis B Immune Globulin (HBIG):
- Approved for post-transplant prophylaxis of hepatitis B in liver transplants.1
- Proven to be safe and effective in preventing HBV recurrence following liver transplants2
- With actual potency indicated on each vial to ensure high dosing accuracy1
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/hepagam5_USA.png)
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/VIAL_hepagam5_USA_lot_70257.png)
References
- Kamada corporate presentation, September 2022
- Terrault NA, Kilic M, Karademir S, et al. HepaGam B after liver transplant in patients with hepatitis B virus. Available at: https://www.researchgate.net/publication/267792129_Orthotopic_HepaGam_B_After_Liver_Transplant_in_Patients_with_Hepatitis_B_Virus. Accessed July 27, 2022
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/varizig-logo.jpg)
![](https://static.sharedirecttech.com/clients/ast9/programs/partnerconnect10/kamada/varizig-iv125-eng-USA.png)
Varicella-zoster virus (VZV) infection remains a significant concern for transplant patients without sufficient VZV immunity1.
VARIZIG® is recommended as first-line treatment by leading guidelines for VZV post-exposure prophylaxis, to effectively reduce disease severity and complications after exposure of a high-risk individual to VZV1-3.
References
- Varicella Zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, 2019.
- The CDC updated Recommendations for Use of VARIZIG - United States, 2013.
- Red-Book: 2021–2024 Report of the Committee on Infectious Diseases.